Bert Vander Cruyssen

3.3k total citations
61 papers, 2.2k citations indexed

About

Bert Vander Cruyssen is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Bert Vander Cruyssen has authored 61 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Rheumatology, 18 papers in Immunology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Bert Vander Cruyssen's work include Rheumatoid Arthritis Research and Therapies (37 papers), Spondyloarthritis Studies and Treatments (19 papers) and Systemic Lupus Erythematosus Research (16 papers). Bert Vander Cruyssen is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (37 papers), Spondyloarthritis Studies and Treatments (19 papers) and Systemic Lupus Erythematosus Research (16 papers). Bert Vander Cruyssen collaborates with scholars based in Belgium, Netherlands and Spain. Bert Vander Cruyssen's co-authors include Dirk Elewaut, Gust Verbruggen, Ruth Wittoek, Nathan Vastesaeger, Filip De Keyser, Eduardo Collantes‐Estévez, Herman Mielants, Filip Van den Bosch, Kurt De Vlam and Dieter Deforce and has published in prestigious journals such as The EMBO Journal, The Journal of Immunology and Gastroenterology.

In The Last Decade

Bert Vander Cruyssen

55 papers receiving 2.1k citations

Peers

Countries citing papers authored by Bert Vander Cruyssen

Since Specialization

Citations

This map shows the geographic impact of Bert Vander Cruyssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert Vander Cruyssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert Vander Cruyssen more than expected).

Fields of papers citing papers by Bert Vander Cruyssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert Vander Cruyssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert Vander Cruyssen. The network helps show where Bert Vander Cruyssen may publish in the future.

Co-authorship network of co-authors of Bert Vander Cruyssen

This figure shows the co-authorship network connecting the top 25 collaborators of Bert Vander Cruyssen. A scholar is included among the top collaborators of Bert Vander Cruyssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bert Vander Cruyssen. Bert Vander Cruyssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome 2025 ·Journal of Thrombosis and Haemostasis ·Lieve Van Hoovels, Silvia Piantoni, Els Bailleul, Sofie Schouwers, Massimo Radin, María Infantino, Emirena Garrafa, (unknown), (unknown), Stefanie Van den Bremt, Bert Vander Cruyssen, Katrien Devreese, Anǵela Tincani, Savino Sciascia, Xavier Bossuyt	0
2	Circulating calprotectin in rheumatoid arthritis: unravelling the impact of (pre-)analytical confounders on meta-analysis results 2024 ·Journal of Laboratory and Precision Medicine ·(unknown), (unknown), Bert Vander Cruyssen, María Infantino, Xavier Bossuyt, Lieve Van Hoovels	0
3	Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type 2021 ·Clinica Chimica Acta ·(unknown), (unknown), Stefanie Van den Bremt, (unknown), Bert Vander Cruyssen, (unknown), Heike Berthold, Christian Konrad, Xavier Bossuyt, Lieve Van Hoovels	20
4	Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab. 2018 ·PubMed ·Harald Peeters, Édouard Louis, Filip Baert, Olivier Dewit, J.-C. Coche, Marc Ferrante, Guy Lambrecht, (unknown), A. Van Gossum, Peter Bossuyt, Tom G. Moreels, Bert Vander Cruyssen, Ann Gils, Martine De Vos	7
5	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial 2018 ·Annals of the Rheumatic Diseases ·M. Kloppenburg, Roberta Ramonda, Klaus Bobacz, Wing‐Yee Kwok, Dirk Elewaut, T. Huizinga, Féline P B Kroon, Leonardo Punzi, Josef S Smolen, Bert Vander Cruyssen, Ron Wolterbeek, Gust Verbruggen, Ruth Wittoek	125
6	Randomised, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept in patients with erosive inflammatory hand osteoarthritis 2017 ·Osteoarthritis and Cartilage ·M. Kloppenburg, Roberta Ramonda, Wing‐Yee Kwok, Klaus Bobacz, Dirk Elewaut, Paola Frallonardo, T. Huizinga, Frank P. Kroon, Josef S Smolen, Bert Vander Cruyssen, Ron Wolterbeek, Leonardo Punzi, Gust Verbruggen, Ruth Wittoek	3
7	A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study 2016 ·PLoS ONE ·Sophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez, Dirk Elewaut, (unknown)	17
8	A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study 2011 ·Ghent University Academic Bibliography (Ghent University) ·Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez, Dirk Elewaut	1
9	Evidence for Significant Overlap between Common Risk Variants for Crohn's Disease and Ankylosing Spondylitis 2010 ·PLoS ONE ·Debby Laukens, Michel Georges, Cécile Libioulle, Cynthia Sandor, Myriam Mni, Bert Vander Cruyssen, Harald Peeters, Dirk Elewaut, Martine De Vos	49
10	Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity 2010 ·Arthritis Research & Therapy ·Bert Vander Cruyssen, Patrick Durez, René Westhovens, Filip De Keyser	25
11	Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery 2009 ·Lara D. Veeken ·Bert Vander Cruyssen, Elisa Muñoz-Gomáriz, Pilar Font, Juan Mulero, Kurt De Vlam, Annelies Boonen, Janitzia Vázquez‐Mellado, D. Flores, Nathan Vastesaeger, Eduardo Collantes‐Estévez	139
12	Xylosan polysulphate as a symptom modifying osteoarthritis drug in patients with finger joint arthritis 2008 ·Ghent University Academic Bibliography (Ghent University) ·Bert Vander Cruyssen, (unknown), (unknown), (unknown), Pranab Ghosh, August Verbruggen	1
13	Over-representation of construction-related occupations in male patients with systemic sclerosis 2008 ·Annals of the Rheumatic Diseases ·Vanessa Smith, Marie Vanthuyne, Bert Vander Cruyssen, Jens Van Praet, (unknown), (unknown), Frédéric Houssiau, Filip De Keyser	15
14	A Single Early Activation of Invariant NK T Cells Confers Long-Term Protection against Collagen-Induced Arthritis in a Ligand-Specific Manner 2007 ·The Journal of Immunology ·Ken Coppieters, Katrien Van Beneden, Peggy Jacques, Pieter Dewint, (unknown), Bert Vander Cruyssen, Serge Van Calenbergh, Guangwu Chen, Richard W. Franck, Gust Verbruggen, Dieter Deforce, Patrick Matthys, Moriya Tsuji, Pieter Rottiers, Dirk Elewaut	49
15	Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis 2007 ·Annals of the Rheumatic Diseases ·Bert Vander Cruyssen, L Nogueira, Jens Van Praet, Dieter Deforce, Dirk Elewaut, Guy Serre, Filip De Keyser	32
16	Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect 2006 ·Annals of the Rheumatic Diseases ·Bert Vander Cruyssen, Patrick Durez, René Westhovens, Filip Van den Bosch, Herman Mielants, Luc S. De Clerck, (unknown), Michel Malaise, Leon Verbruggen, (unknown), Anja Geldhof, Filip De Keyser	1
17	Clinical assessment in the spondyloarthropathies, including psoriatic arthritis 2006 ·Current Opinion in Rheumatology ·Filip Van den Bosch, Bert Vander Cruyssen, Herman Mielants	2
18	Potent anti-inflammatory, fully dissociative compound for glucocorticoid receptor-mediated gene regulation 2005 ·Ghent University Academic Bibliography (Ghent University) ·Pieter Dewint, Karolien De Bosscher, (unknown), Wim Vanden Berghe, Bert Vander Cruyssen, Eric Veys, Guy Haegeman, Dirk Elewaut	2
19	Comparing statistics with machine learning models to predict dose increase of infliximab for rheumatoid arthritis patients 2005 ·Ghent University Academic Bibliography (Ghent University) ·Stijn Van Looy, Bert Vander Cruyssen, Bart Wyns, (unknown), Filip De Keyser, Luc Boullart	1
20	Comparison of Machine Learning models for prediction of dose increase in patients with rheumatoid arthritis 2005 ·Ghent University Academic Bibliography (Ghent University) ·Stijn Van Looy, (unknown), Bart Wyns, Bert Vander Cruyssen, Luc Boullart, Filip De Keyser	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact